This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (43)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Oncology  • Skin Cancer  • Prognosis/ Outcomes  • Alert me on articles by topic  Social Bookmarking   What's this?

A Multicenter Collaborative Study

Juan-Carlos Martinez, BA; Clark C. Otley, MD; Thomas Stasko, MD; Sylvie Euvrard, MD; Christine Brown, MD; Carl F. Schanbacher, MD; Amy L. Weaver, MS; for the Transplant–Skin Cancer Collaborative

Arch Dermatol. 2003;139:301-306.

Objective  To evaluate the demographic characteristics, clinical course, and outcome in organ transplant recipients with metastatic skin cancer.

Design and Setting  An international, multicenter, Internet-coordinated collaborative group retrospectively analyzed data from 68 organ transplant recipients with 73 distinct metastatic skin cancers.

Main Outcome Measurements  The Kaplan-Meier method was used to estimate the cumulative incidence of relapse, overall survival, and disease-specific survival after metastatic skin cancer. Univariate Cox proportional hazards models were fit to evaluate factors for an association with survival.

Results  Metastasis from skin cancer in organ transplant recipients most commonly consisted of squamous cell carcinoma in regional nodal basins. It was predominantly treated with a combination of surgery and irradiation. By 1 year after metastasis, the cumulative incidence of relapse was 29%, and the 3-year disease-specific survival was 56%. Patients whose initial metastases were distant or systemic had a significantly poorer disease-specific survival than those whose initial metastases were in-transit or regional (risk ratio, 6.5; P<.001).

Conclusions  Metastatic skin cancer in organ transplant recipients has a poor prognosis. Preventive, early, and aggressive therapeutic interventions are required to minimize this serious complication of transplant-associated immunosuppression.

From the Mayo Medical School (Mr Martinez) and Mayo Clinic (Dr Otley and Ms Weaver), Rochester, Minn; Vanderbilt University School of Medicine, Nashville, Tenn (Dr Stasko); Hôpital Edouard Herriot, Lyon, France (Dr Euvrard); Baylor University Medical Center, Houston, Tex (Dr Brown); and Brigham and Women's Hospital, Boston, Mass (Dr Schanbacher). The authors have no relevant financial interest in this article.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Adenosquamous Carcinoma of the Skin: A Case Series
Fu et al.
Arch Dermatol 2009;145:1152-1158.
ABSTRACT | FULL TEXT  

First and subsequent nonmelanoma skin cancers: incidence and predictors in a population of New Zealand renal transplant recipients
Mackenzie et al.
Nephrol Dial Transplant 2009;0:gfp482v1-gfp482.
ABSTRACT | FULL TEXT  

Context-dependent regulation of cutaneous immunological responses by TGF{beta}1 and its role in skin carcinogenesis
Glick et al.
Carcinogenesis 2008;29:9-14.
ABSTRACT | FULL TEXT  

Sentinel Lymph Node Biopsy for Evaluation and Treatment of Patients With Merkel Cell Carcinoma: The Dana-Farber Experience and Meta-analysis of the Literature.
Gupta et al.
Arch Dermatol 2006;142:685-690.
ABSTRACT | FULL TEXT  

Amelioration of Acute Renal Failure by Stem Cell Therapy--Paracrine Secretion Versus Transdifferentiation into Resident Cells: Administered Mesenchymal Stem Cells Protect against Ischemic Acute Renal Failure through Differentiation-Independent Mechanisms. Am J Physiol Renal Physiol E-pub February 15, 2005
Togel et al.
J. Am. Soc. Nephrol. 2005;16:1153-1163.
FULL TEXT  

Skin Cancers after Organ Transplantation
Euvrard et al.
NEJM 2003;348:1681-1691.
FULL TEXT  

Metastatic Cutaneous Cancer in Transplant Recipients: A Poor Prognosis
Journal Watch Dermatology 2003;2003:8-8.
FULL TEXT